# US 2021/0239716 A1 · A method of diagnosing or prognosing a neurological disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0239716 A1
- Document ID: US20210239716A1
- Status: Published application
- Kind: A1
- Application number: 17/052,074
- Filed: 2019-05-01
- Published: 2021-08-05
- Earliest claimed: 2018-05-01
- Assignees: University of Ulster
- Applicants: University of Ulster
- Inventors: Stephanie DUGUEZ; William DUDDY
- Web page: https://patentgrep.com/patent/US20210239716A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/158: Expression markers
- G01N 2800/28: Neurological disorders
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- G01N 2800/285: Demyelinating diseases; Multipel sclerosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a method of diagnosing or prognosing a neurological disorder in a subject. The method comprises determining the quantitative or qualitative level of one or more biomarkers in a biological sample from the subject; and diagnosing or prognosing the neurological disorder in the subject based on the quantitative or qualitative level of the or each biomarker in the biological sample.

## Claims

### Claim 1

A method of diagnosing or prognosing a neurological disorder in a subject, the method comprising the steps of:
(a) determining the quantitative or qualitative level of one or more biomarkers in a biological sample from the subject; and
(b) diagnosing or prognosing the neurological disorder in the subject based on the quantitative or qualitative level of the or each biomarker in the biological sample;
wherein the or each biomarker is selected from: PDIA3; CCDC80; HSPA8; SERPINE2; PLEC; HSPA5; NCL; TPM1; TNC; IGFBP3; COL5A1; CLEC11A; MAP1B; NACA; PSMA2; RPL5; MYL6; CTSB; HSPD1; PTRF; NUCB1; PDIA4; P4HB; ACTN4; CAPRIN1; DES; APP; and DAG1.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the determining step (a) comprises determining the quantitative or qualitative level of all of the biomarkers in the biological sample from the subject.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the determining step (a) comprises determining the quantitative or qualitative level of each of the biomarkers in the biological sample from the subject.

### Claim 4 (depends on 1)

The method according to claim 1,
wherein the or each biomarker is a gene.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the or each biomarker is a gene selected from: PDIA3; CCDC80; HSPA8; SERPINE2; PLEC; DES; APP; and DAG1.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the or each biomarker is a protein encoded by a gene selected from: PDIA3; CCDC80; HSPA8; SERPINE2; PLEC; HSPA5; NCL; TPM1; TNC; IGFBP3; COL5A1; CLEC11A; MAP1B; NACA; PSMA2; RPL5; MYL6; CTSB; HSPD1; PTRF; NUCB1; PDIA4; P4HB; ACTN4; CAPRIN1; DES; APP; and DAG1.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the or each biomarker is a protein encoded by a gene selected from: PDIA3; CCDC80; HSPA8; SERPINE2; PLEC; and DAG1

### Claim 8 (depends on 6)

The method according to claim 6, wherein the or each biomarker is a protein having a UniProtKB/Swiss-Prot Accession Number selected from: P30101; Q76M96; P11142; P07093; Q15149; P11021; P19338; P09493; P24821; P17936; P20908; Q9Y240; P46821; Q13765; P25787; P46777; P60660; P07858; P10809; Q6NZI2; Q02818; P13667; P07237; 043707; Q14444; P17661; P05067; and Q14118.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the or each biomarker is a protein having a UniProtKB/Swiss-Prot Accession Number selected from: P30101; Q76M96; P11142; P07093; Q15149; P17661; P05067; and Q14118.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the neurological disorder is a neurodegenerative disorder.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the neurodegenerative disorder is selected from amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease; motor neurone disease; MND), hereditary spastic paraplegia (HSP), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), progressive bulbar palsy (PBP), pseudobulbar palsy, spinal-bulbar muscular atrophy (SBMA), and spinal muscular atrophy.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the diagnosing or prognosing step (b) comprises comparing the quantitative or qualitative level of the or each biomarker in the biological sample from the subject with the quantitative or qualitative level of the or each respective biomarker in a normal sample.

### Claim 13 (depends on 12)

The method according to claim 12, wherein a quantitative or qualitative level of the or each biomarker in the biological sample from the subject greater than the quantitative or qualitative level of the or each respective biomarker in a normal sample is indicative of the quantitative or qualitative presence of the neurological disorder.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the biological sample is selected from whole blood, serum, plasma, urine, interstitial fluid, peritoneal fluid, cervical swab, tears, saliva, buccal swab, skin, brain tissue, and cerebrospinal fluid.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the biological sample is whole blood.
